Authors suggest that despite being approved by the FDA, there is little rationale to prescribe these drugs for the treatment of tardive dyskinesia.
Valbenazine and duetrabenazine are not currently licensed for use in the EU. Tetrabenazine is licensed in the UK for the treatment of moderate to severe tardive dyskinesia. This study however did not identify and randomised trials of tetrabenazine in patients with tardive dyskinesia and could therefore not perform an economic review for this treatment.